Tags

Type your tag names separated by a space and hit enter

Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
MMWR Morb Mortal Wkly Rep 2011; 60(48):1650-3MM

Abstract

Preventing tuberculosis (TB) by treating latent Mycobacterium tuberculosis infection (LTBI) is a cornerstone of the U.S. strategy for TB elimination. Three randomized controlled trials have shown that a new combination regimen of isoniazid (INH) and rifapentine (RPT) administered weekly for 12 weeks as directly observed therapy (DOT) is as effective for preventing TB as other regimens and is more likely to be completed than the U.S. standard regimen of 9 months of INH daily without DOT. This report provides CDC recommendations for using the INH-RPT regimen. The new regimen is recommended as an equal alternative to the 9-month INH regimen for otherwise healthy patients aged≥12 years who have LTBI and factors that are predictive of TB developing (e.g., recent exposure to contagious TB). The new regimen also can be considered for other categories of patients when it offers practical advantages. Although the INH-RPT regimen was well tolerated in treatment trials, monitoring for adverse effects is recommended. Severe adverse effects should be reported to the Food and Drug Administration (FDA) and CDC.

Authors

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

22157884

Citation

Centers for Disease Control and Prevention (CDC). "Recommendations for Use of an Isoniazid-rifapentine Regimen With Direct Observation to Treat Latent Mycobacterium Tuberculosis Infection." MMWR. Morbidity and Mortality Weekly Report, vol. 60, no. 48, 2011, pp. 1650-3.
Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650-3.
Centers for Disease Control and Prevention (CDC). (2011). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR. Morbidity and Mortality Weekly Report, 60(48), pp. 1650-3.
Centers for Disease Control and Prevention (CDC). Recommendations for Use of an Isoniazid-rifapentine Regimen With Direct Observation to Treat Latent Mycobacterium Tuberculosis Infection. MMWR Morb Mortal Wkly Rep. 2011 Dec 9;60(48):1650-3. PubMed PMID: 22157884.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. A1 - ,, PY - 2011/12/14/entrez PY - 2011/12/14/pubmed PY - 2012/1/21/medline SP - 1650 EP - 3 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb. Mortal. Wkly. Rep. VL - 60 IS - 48 N2 - Preventing tuberculosis (TB) by treating latent Mycobacterium tuberculosis infection (LTBI) is a cornerstone of the U.S. strategy for TB elimination. Three randomized controlled trials have shown that a new combination regimen of isoniazid (INH) and rifapentine (RPT) administered weekly for 12 weeks as directly observed therapy (DOT) is as effective for preventing TB as other regimens and is more likely to be completed than the U.S. standard regimen of 9 months of INH daily without DOT. This report provides CDC recommendations for using the INH-RPT regimen. The new regimen is recommended as an equal alternative to the 9-month INH regimen for otherwise healthy patients aged≥12 years who have LTBI and factors that are predictive of TB developing (e.g., recent exposure to contagious TB). The new regimen also can be considered for other categories of patients when it offers practical advantages. Although the INH-RPT regimen was well tolerated in treatment trials, monitoring for adverse effects is recommended. Severe adverse effects should be reported to the Food and Drug Administration (FDA) and CDC. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/22157884/full_citation L2 - https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm DB - PRIME DP - Unbound Medicine ER -